Loading
Camrelizumab is Jiangsu Hengrui's humanised PD-1 antibody, approved in China for oesophageal, liver and lung cancer but not in the US, where its liver cancer combination with rivoceranib drew complete response letters in 2024 and 2025 over manufacturing and inspection issues. Its signature side effect is reactive cutaneous capillary endothelial proliferation, a skin reaction seen in most patients.
Humanised IgG4 anti-PD-1 (Jiangsu Hengrui). ESCORT (second-line ESCC) and ESCORT-1st (first-line with chemotherapy, OS 15.3 vs 12.0 months) in China; ESCORT-NEO neoadjuvant; CARES-310 with rivoceranib in HCC (OS 22.1 vs 15.2 months). A US BLA for the HCC combination received complete response letters (2024, 2025) over manufacturing and travel-inspection issues. Distinctive toxicity: reactive cutaneous capillary endothelial proliferation (RCCEP) in most patients.
Backbone ribbon from PDB 7CU5. RCSB PDB 7CU5. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
PD-1 blockade. Connects to PD-1.
1.Camrelizumab binds PD-1 on T cells
Not FDA-approved, so there is no US coverage; access is only through a clinical trial or an FDA expanded-access request.
Not FDA-approved, so there is no US coverage; access is only through a clinical trial or an FDA expanded-access request.
Sources: CMS Medicare Coverage Database (NCDs and LCDs). Not medical or financial advice; verify with your plan.
Sources: NICE search: camrelizumab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Complete response letter for camrelizumab + rivoceranib in HCC (manufacturing/inspection)
Second complete response letter
| Region | Year | Indication |
|---|---|---|
| China | 2019 | Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal |
| Adverse event |
|---|
| Reactive cutaneous capillary endothelial proliferation (RCCEP) |
| Immune-related adverse events |
Very common; benign, resolves after stopping. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Camrelizumab" OR ABSTRACT:"Camrelizumab" OR TITLE:"AiRuiKa" OR ABSTRACT:"AiRuiKa" OR TITLE:"SHR-1210" OR ABSTRACT:"SHR-1210") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Camrelizumab, not a curated reading list.
Shares Li Zhang, Wenfeng Fang, Rui-Hua Xu, CAPTAIN-1st.
Shares Li Zhang, Rui-Hua Xu, Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer, CSCO guidelines (China).
Shares Rui-Hua Xu, CSCO guidelines (China), Oesophageal cancer, Hepatocellular carcinoma.
Shares CAPTAIN-1st, Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, PD-1.
Shares Jing Huang, CSCO guidelines (China), Regulatory divergence between regions, Oesophageal cancer.
Shares Li Zhang, Wenfeng Fang, PD-1, Non-small-cell lung cancer.
Shares CSCO guidelines (China), Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, PD-1.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, PD-1, Hepatocellular carcinoma.